The WIRB-Copernicus Group’s (WCG) clinical services division said it has begun to market its benchmarking solution to medical device companies for use in clinical trials.
The software is designed to reduce study costs and improve performance. It has already enabled 27 biopharma companies to reduce operational cycle-times up to 20%, decrease study costs by 15%, and improve their ranking against peers by 30%, according to the Princeton, N.J.-based company.
WCG’s KMR Group provides the benchmarking data, metrics and analytics as well as online analytics tools that enable access to proprietary and rich datasets, the company said in a news release. Chicago-based KMR’s clinical platform has information on nearly 30,000 global clinical trials. It is designed to enable detailed performance reports including:
- All phases of research.
- All countries, including emerging markets.
- All diseases, including differentiating rare diseases.
- Site types (institutional vs. independent).
- Management type (managed directly by the sponsor or via contract research organization).
The platform also offers a qualitative survey to bridge performance details and operational factors, including payments and use of master agreements.
“We are thrilled to now offer our site contracts program to medical device companies,” said KMR Group president Linda Martin. “This program will give device companies a rock-solid foundation of proprietary, independently verified data on which to build their study plans and implement performance improvements, as well as unique evidence-based insights to guide their decision-making. Our unique data-driven approach, supported by a softer issues-based survey, is a must for any organization committed to accelerating clinical research.”
